Gene transfer of pro-IL-18 and IL-1beta converting enzyme cDNA induces potent antitumor effects in L1210 cells.
We report in a murine model of acute lymphoid leukemia L1210 the potent antitumor efficiency of a combinatorial delivery of pro-IL-18 gene modified L1210 (Lp18) and IL-1beta converting enzyme (ICE) gene modified L1210 (LpICE). Live leukemia cells Lp18 or Lp18 plus LpICE showed apparently reduced leukemogenicity with a survival rate of 40 or 50% at 50 days after intraperitoneal (i.p.) inoculation of a lethal dose of cells, respectively. Combination of Lp18 and LpICE was capable of inhibiting accumulation of bloody ascites, synergistically superior to Lp18 or LpICE alone. All surviving mice were rechallenged with parental L1210 cells at day 50, and all survived up to day 80, suggesting that gene-modified cells induced immune protection. Moreover, NK cytotoxicity and CTL activity were both enhanced in mice injected with Lp18, especially Lp18 plus LpICE. Levels of IFN-gamma were not altered significantly by inoculation of Lp18 or Lp18 plus LpICE. Our results demonstrate that IL-18 is a useful candidate gene in gene therapy of lymphoma or lymphoid leukemia, and ex vivo combinatorial delivery of Lp18 plus LpICE either as a single approach or as an adjunct to concomitant radiotherapy or chemotherapy, may be more efficient in a situation of minimal residual disease.
National Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
B
B
Zhang
K-F
KF
Wu
Y-M
YM
Lin
X-T
XT
Ma
Q
Q
Rao
G-G
GG
Zheng
Z-Y
ZY
Cao
G
G
Li
Y-H
YH
Song
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology; D001201:Ascites; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D018076:DNA, Complementary; D010450:Endopeptidases / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D020382:Interleukin-18 / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology; D007945:Leukemia, Lymphoid / Q000473:pathology* / Q000628:therapy*; D051379:Mice; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D009419:Nerve Tissue Proteins / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology; D014162:Transfection; D053148:Caspase 3
D000970:Antineoplastic Agents; D018076:DNA, Complementary; D010450:Endopeptidases; D020382:Interleukin-18; D009419:Nerve Tissue Proteins; C505410:Casp3 protein, rat; D053148:Caspase 3